{
    "leverage": true,
    "derivatives": true,
    "swaps": false,
    "inverse": true,
    "replication_method": "synthetic",
    "ucits": false,
    "type": "ETP",
    "complex_factors": "Leverage, Derivatives, Synthetic Replication, Compounding Effect, Futures Exposure, Roll Costs, High Risk Profile",
    "classification": "complex",
    "supporting_data": "The product is a leveraged (5x daily) inverse ETP tracking US Treasury futures, not a UCITS. It uses synthetic replication via futures contracts, introducing significant leverage, compounding effects, and roll costs. The structure is not straightforward for retail investors to understand, especially given the daily reset and the potential for returns to deviate significantly from the index over time due to compounding. The product is intended for informed investors, carries the highest risk rating (7/7), and explicitly warns that it is not simple and may be difficult to understand. These featuresu2014leverage, synthetic replication, futures exposure, and compoundingu2014make the product complex under MiFID II Article 57 criteria, as it involves actual or potential liability beyond the cost of acquisition, frequent opportunities to realize the instrument at market prices, but with a structure and risk profile that are not easily understood by the average retail client. The product does not embed swaps or contingent convertible bonds, but the central use of futures and the inverse, leveraged strategy are decisive for complexity."
}